|1.||Goda, Toshinao: 10 articles (09/2014 - 10/2007)|
|2.||Mochizuki, Kazuki: 10 articles (09/2014 - 10/2007)|
|3.||Fuchigami, Masahiro: 6 articles (09/2014 - 12/2009)|
|4.||Fukaya, Nanae: 6 articles (11/2011 - 06/2009)|
|5.||Tanaka, Yutaro: 4 articles (11/2011 - 07/2009)|
|6.||Terauchi, Yasuo: 3 articles (11/2014 - 01/2010)|
|7.||Osonoi, Takeshi: 3 articles (09/2014 - 12/2010)|
|8.||Saito, Miyoko: 3 articles (09/2014 - 12/2010)|
|9.||Fujiwara, Hisayoshi: 3 articles (09/2011 - 07/2004)|
|10.||Minatoguchi, Shinya: 3 articles (09/2011 - 07/2004)|
|1.||Type 2 Diabetes Mellitus (MODY)
03/01/2000 - "Clinical trials with miglitol (usually 50 or 100 mg 3 times daily) in patients with type 2 diabetes mellitus consistently demonstrated a significant improvement in glycaemic control for periods of 6 to 12 months. "
11/01/2000 - "Miglitol is an effective and safe treatment option in patients with type 2 diabetes mellitus who are inadequately controlled with diet or oral sulfonylurea therapy. "
05/01/1997 - "Miglitol monotherapy is effective and safe in NIDDM patients. "
03/01/2011 - "Results of this study indicate that miglitol significantly improves metabolic control in Chinese patients with type 2 diabetes mellitus. "
03/01/2011 - "The objective of this study is to examine the efficacy and tolerability of miglitol with respect to improving glycemic control in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylurea treatment. "
01/01/2012 - "In conclusion, 3-month repeated administration of miglitol improved vascular endothelial dysfunction by strongly suppressing postprandial hyperglycemia. "
07/01/1986 - "Thus, in a one-day study 50 mg of Bay m 1099 reduced the postprandial hyperglycemia in NIDDs. "
12/13/2012 - "Furthermore, α-1-C-butyl-LAB strongly suppressed postprandial hyperglycemia at an early phase, similar to miglitol in vivo. "
06/05/2011 - "Thus, combined treatment with the α-GI miglitol, which more strongly inhibits the early phase of postprandial hyperglycemia, and DPP4 inhibitor yields both complementary and synergistic effects, and might represent a superior anti-hyperglycemic therapy. "
01/01/2011 - "Miglitol has been shown to have a beneficial effect on postprandial hyperglycemia in diabetic patients. "
01/01/2015 - "Overall, we demonstrate that miglitol shows good potential as a therapeutic for the treatment of obesity. "
01/01/2014 - "Recent studies have shown that miglitol reduces obesity in humans and rodents. "
01/01/2015 - "In this review, we provide an overview of the state of research on miglitol for obesity treatment, emphasizing that it warrants more detailed attention. "
01/01/2015 - "Among these results, we consider that BAT activation is likely the definitive mediator of miglitol's anti-obesity effect. "
01/01/2015 - "Review: Miglitol has potential as a therapeutic drug against obesity."
|4.||Hypoglycemia (Reactive Hypoglycemia)
01/01/2004 - "A decrease in the number of hypoglycemia episodes (39.4% previous quarter versus 3% quarter wih miglitol) was observed. "
11/28/2014 - "Using miglitol at 30 min before meal is effective in hyperinsulinemic hypoglycemia after a total gastrectomy."
11/28/2014 - "In this report, we propose a new therapeutic approach for reactive hypoglycemia after gastrectomy, namely, administration of miglitol 30 min before meals."
11/28/2014 - "Since hypoglycemia following gastrectomy is thought to be caused by rapid delivery of nutrients into the duodenum, we performed a meal tolerance test while varying the timing of administration of miglitol in relation to the meal. "
01/01/2012 - "In conclusion, the administration of miglitol was effective for preventing reactive hypoglycemia secondary to late dumping syndrome."
11/01/2007 - "Body mass index (BMI) tended to decrease with miglitol (P = .06), and homeostasis model assessment of insulin resistance and AER significantly decreased (P < .05 and P < .001, respectively) with miglitol; these changes were not obtained with mitiglinide. "
06/01/1999 - "Glucose tolerance and insulin resistance in the JCR:LA-corpulent rat: effect of miglitol (Bay m1099)."
01/01/2015 - "Miglitol has been shown to reduce body weight and ameliorate insulin resistance in both clinical trials with adult patients and in rodent models of obesity. "
05/01/2013 - "The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice."
11/01/2007 - "The present comparative study indicated favorable effects of miglitol on BMI, homeostasis model assessment of insulin resistance, adiponectin, and AER, which are markers related to insulin resistance and atherosclerosis. "
|2.||alpha-Glucosidases (Acid Maltase)
|9.||Interleukin-18 (Interleukin 18)
|10.||Glucagon-Like Peptide 1 (GLP 1)
|2.||Exercise Therapy (Therapy, Exercise)